ZHAO Wenshuo 1,2 , LIU Ming 3,4,5 , GE Long 6,7 , LI Lun 8,9 , SHI Jiyuan 10 , YANG Fengwen 11,12 , TIAN Jinhui 4,5 , XUE Fuzhong 1,2,13 , GAO Ya 1,2
  • 1. Department of Medical Dataology, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, P. R. China;
  • 2. National Institute of Health and Medical Big Data, Jinan 250003, P. R. China;
  • 3. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore;
  • 4. Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University,Lanzhou 730000, P. R. China;
  • 5. Key Laboratory of Evidence-Based Medicine of Gansu Province, Lanzhou 730000, P. R. China;
  • 6. Department of Health Policy and Management, School of Public Health, Lanzhou University, Lanzhou 730000, P. R. China;
  • 7. Center for Evidence-Based Social Science, Lanzhou University, Lanzhou 730000, P. R. China;
  • 8. Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha 410010, P. R. China;
  • 9. Clinical Research Center of Hunan Province, Changsha 410011, P. R. China;
  • 10. School of Nursing, Beijing University of Traditional Chinese Medicine, Beijing 100029, P. R. China;
  • 11. Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P. R. China;
  • 12. Key Laboratory of Evidence-Based Evaluation of Traditional Chinese Medicine, National Medical Products Administration, Tianjin 301617, P. R. China;
  • 13. Qilu Hospital of Shandong University, Jinan 250012, P. R. China;
GAO Ya, Email: gaoy2021@163.com
Export PDF Favorites Scan Get Citation

The consolidated standards of reporting trials (CONSORT) is an internationally recognized guideline for reporting randomized controlled trials (RCTs), aiming to enhance the transparency, completeness, and reliability of trial findings. In response to the ongoing evolution of clinical trial methodology, the CONSORT group has issued updates to the CONSORT statement in 2001, 2010, and most recently in 2025. This article provides an applied interpretation of the background and key components of the CONSORT 2025 statement through the lens of a representative randomized controlled trial, with the aim of offering practical guidance and reference for domestic researchers utilizing this reporting tool.

Copyright © the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved